The course of COVID-19 in patients with chronic spontaneous urticaria receiving omalizumab treatment

BACKGROUND AND AIM: Although there are case reports and guideline recommendations that states omalizumab can be used in chronic spontaneous urticaria (CSU) patients during SARS-CoV-2 pandemic, there are scarce studies showing the course of Coronavirus disease 2019 (COVID-19) in CSU patients receivin...

Descripción completa

Detalles Bibliográficos
Autores principales: Atayik, E., Aytekin, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Masson SAS. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189112/
https://www.ncbi.nlm.nih.gov/pubmed/35721324
http://dx.doi.org/10.1016/j.reval.2022.06.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189112/
https://www.ncbi.nlm.nih.gov/pubmed/35721324
http://dx.doi.org/10.1016/j.reval.2022.06.003

Ejemplares similares